$2.73
+0.08 (+2.82%)
Open$2.69
Previous Close$2.66
Day High$2.75
Day Low$2.66
52W High$4.00
52W Low$2.10
Volume—
Avg Volume126.1K
Market Cap272.75M
P/E Ratio—
EPS$-0.43
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+771.1% upside
Current
$2.73
$2.73
Target
$23.78
$23.78
$21.93
$23.78 avg
$37.21
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.63M | 3.73M | 119.79M |
| Net Income | -71,426,597 | -66,190,215 | 199.8K |
| Profit Margin | -1,971.7% | -1,873.1% | 0.2% |
| EBITDA | -67,749,027 | -66,270,156 | 316.5K |
| Free Cash Flow | — | — | 248.3K |
| Rev Growth | -2.9% | -2.9% | -0.9% |
| Debt/Equity | 0.10 | 0.10 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |